AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 131 min read$TWST

Laponis Adam sold $385K of TWST

Laponis Adam (Chief Financial Officer) sold 2,462 shares of Twist Bioscience Corp (TWST) at $156.30 ($0.38M total) on 2026-10-09.

Original reporting
SEC EDGAR · Laponis Adam
Published Oct 13, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TWST
Bearish
medium confidence
Mentioned
$TWST
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTBearishLow
01

Why it matters

The transaction reduces insider ownership and may be interpreted as a negative signal, but the modest size limits market reaction.

02

Market read

Primary insider sale filing; modest size, low immediate trading relevance.

03

What to watch

No 10b5‑1 plan was used, suggesting the sale was discretionary.

Relevance 4/10Novelty 4/10Timing: post‑market today

Background

SEC Form 4 filings disclose insider transactions. This filing reports a CFO's open‑market sale of TWST shares.

Company-level read

Ticker impact

$TWSTBearishMedium confidence
Context

CFO Adam Laponis sold 2,462 shares for $384,823, reducing his stake to 98,114 shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

The sale is a primary Form 4 filing, but the amount ($385K) is modest for a mid‑cap, so impact is limited.

Market effects

Sector

Minimal; the sale does not affect the broader biotech sector.

Regional

None; the filing is company‑specific.

Global

Low; only relevant to Twist Bioscience investors.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing unrelated to company fundamentals.

Key entities

  • company
    Twist Bioscience Corp

    Biotech company developing synthetic DNA platforms.

  • person
    Adam Laponis

    Chief Financial Officer of Twist Bioscience.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TWST insider trading history →

Related articles

OCT 8
$TWSTMed

Jefferies initiates Twist Bioscience stock at Hold on valuation

Jefferies initiated coverage on Twist Bioscience (TWST) with a Hold rating and $150 price target, citing premium valuation. The stock trades at $155.65 after a 391% YTD surge. Jefferies notes its market differentiation and AI-driven growth, but warns of high valuation expectations. TWST partners with Eli Lilly's TuneLab for AI/ML drug discovery, while BWS Financial rates it Sell, and Guggenheim reiterates Buy.

investing.com2 min
OCT 5
$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.

timothysykes.com3 min